Compare CDMOs with rare disease manufacturing expertise for orphan drugs, enzyme replacement therapies, gene therapies, and ultra-small batch production. Filter by modality, scale, and regulatory experience.
Rare disease (orphan drug) manufacturing presents unique challenges. Patient populations are small -- often under 10,000 patients worldwide -- so batch sizes are correspondingly small. But the manufacturing complexity is often extreme: gene therapies, enzyme replacement therapies, substrate reduction therapies, and RNA therapeutics dominate the pipeline. The cost per dose can exceed $100,000, making manufacturing efficiency and batch success rates critically important.
Gene therapy is reshaping rare disease treatment. Over 30 approved gene therapies target rare diseases, with hundreds more in clinical development. Manufacturing AAV vectors for conditions like spinal muscular atrophy, hemophilia, and inherited retinal dystrophy requires specialized viral vector production facilities, scalable purification processes, and potency assays specific to each product. CDMOs with flexible, multi-product vector manufacturing capabilities are in high demand.
Flexibility beats scale for rare disease CDMOs. Unlike cardiovascular or diabetes drugs that need massive throughput, rare disease products need CDMOs that can efficiently handle 10-100 batch campaigns per year. Multi-product facilities with short changeover times, validated cleaning procedures for potent and biologic products, and regulatory experience with orphan drug designations (FDA, EMA) provide the most value to sponsors in this space.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.